BioPharmSignal logoBioPharmSignal

Biotech News

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Therapeutics (CMPX)Compass TherapeuticsCompany update

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Related news

CMPXCompass Therapeutics2026-09-22 12:30 EST

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

GERNGeron2026-10-19 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-10-02 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-10-01 21:10 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDYAIDEAYA Biosciences2026-09-25 10:00 EST

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

URGNUroGen Pharma2026-09-04 12:00 EST

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-10-02 11:00 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

View all latest news

Compass Therapeutics

Antibody-Based Oncology Compass Therapeutics develops antibody therapies at the intersection of angiogenesis, tumor immunity and immune suppression. Its portfolio includes bispecific antibodies and immune activators intended to disrupt tumor blood supply while restoring antitumor immune activity. Tovecimig Tovecimig is a DLL4 and VEGF-A...

Recent company news

CMPXCompass Therapeutics2026-10-14 20:30 EST

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CMPXCompass Therapeutics2026-09-22 12:30 EST

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

CMPXCompass Therapeutics2026-05-28 11:30 EST

Compass Therapeutics to Participate in Upcoming June Investor Events

Stock data

Close
0.81 USD
Market cap
374.58M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States